Benjamin Halladay, Chief Financial Officer at Esperion Therapeutics, Inc. (ESPR), sold 11 shares at $1.86 ($20) on 2025-02-19, disclosed to the SEC on 2025-02-20.
Open-market sale of $20 ESPR by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| ESPR | SELL | 2025-12-18 | $27K | — | Filing → |
| ESPR | SELL | 2025-09-18 | $20K | — | Filing → |
| ESPR | SELL | 2025-07-18 | $12 | — | Filing → |